BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S, Paz-Ares L. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Sci Rep 2018;8:2394. [PMID: 29402970 DOI: 10.1038/s41598-018-20570-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Jeong SY, Jang HJ, Park ST, Kim HS. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:762528. [PMID: 34737965 DOI: 10.3389/fonc.2021.762528] [Reference Citation Analysis]
2 Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148 [PMID: 30949443 DOI: 10.5306/wjco.v10.i3.136] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Xiong J, Xing S, Dong Z, Niu L, Xu Q, Li Y, Liu P, Yang P. miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer. Mol Med Rep 2021;23:124. [PMID: 33300072 DOI: 10.3892/mmr.2020.11763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. J Exp Clin Cancer Res 2018;37:195. [PMID: 30119639 DOI: 10.1186/s13046-018-0871-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
5 Quintanal-villalonga A, Ferrer I, Molina-pinelo S, Paz-ares L. A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opinion on Therapeutic Patents 2019;29:429-38. [DOI: 10.1080/13543776.2019.1624720] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Polak KL, Chernosky NM, Smigiel JM, Tamagno I, Jackson MW. Balancing STAT Activity as a Therapeutic Strategy. Cancers (Basel) 2019;11:E1716. [PMID: 31684144 DOI: 10.3390/cancers11111716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Quintanal-Villalonga A, Molina-Pinelo S, Yagüe P, Marrugal Á, Ojeda-Márquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer 2019;131:112-21. [PMID: 31027687 DOI: 10.1016/j.lungcan.2019.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ferguson HR, Smith MP, Francavilla C. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. Cells 2021;10:1201. [PMID: 34068954 DOI: 10.3390/cells10051201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif 2021;54:e13009. [PMID: 33655556 DOI: 10.1111/cpr.13009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Latko M, Czyrek A, Porębska N, Kucińska M, Otlewski J, Zakrzewska M, Opaliński Ł. Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. Cells 2019;8:E455. [PMID: 31091809 DOI: 10.3390/cells8050455] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
11 Kapeleris J, Kulasinghe A, Warkiani ME, Oleary C, Vela I, Leo P, Sternes P, O'Byrne K, Punyadeera C. Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. Transl Lung Cancer Res 2020;9:1795-809. [PMID: 33209602 DOI: 10.21037/tlcr-20-521] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. WIREs Mech Dis 2022;:e1549. [PMID: 35142107 DOI: 10.1002/wsbm.1549] [Reference Citation Analysis]
13 Hu Y, Li R, Chen H, Chen L, Zhou X, Liu L, Ju M, Chen K, Huang D. Comprehensive analysis of lncRNA-mRNAs co-expression network identifies potential lncRNA biomarkers in cutaneous squamous cell carcinoma. BMC Genomics 2022;23:274. [PMID: 35392800 DOI: 10.1186/s12864-022-08481-0] [Reference Citation Analysis]
14 Ye Y, Li J, Jiang D, Li J, Xiao C, Li Y, Han C, Zhao C. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition. Cancer Res Treat 2020;52:1162-77. [PMID: 32599983 DOI: 10.4143/crt.2020.138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Quintanal-Villalonga Á, Ferrer I, Guruceaga E, Cirauqui C, Marrugal Á, Ojeda L, García S, Zugazagoitia J, Muñoz-Galván S, Lopez-Rios F, Montuenga L, Vicent S, Molina-Pinelo S, Carnero A, Paz-Ares L. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine 2020;53:102683. [PMID: 32114392 DOI: 10.1016/j.ebiom.2020.102683] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: A promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther 2020;214:107590. [PMID: 32492514 DOI: 10.1016/j.pharmthera.2020.107590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Akdeniz Odemis D, Tuncer SB, Adamnejad Ghafour A, Jabbarli K, Gider Y, Celik B, Kuru Turkcan G, Sukruoglu Erdogan O, Kilic Erciyas S, Avsar M, Kebudi R, Buyukkapu Bay S, Tuncer S, Yazici H. FGFR4 c.1162G > A (p.Gly388Arg) Polymorphism Analysis in Turkish Patients with Retinoblastoma. J Oncol 2020;2020:9401038. [PMID: 33456465 DOI: 10.1155/2020/9401038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Szymczyk J, Sluzalska KD, Materla I, Opalinski L, Otlewski J, Zakrzewska M. FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers (Basel) 2021;13:5796. [PMID: 34830951 DOI: 10.3390/cancers13225796] [Reference Citation Analysis]
19 Bian Y, Li Q, Li Q, Pan R. Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells. Mol Med Rep 2020;22:1767-74. [PMID: 32705258 DOI: 10.3892/mmr.2020.11285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]